Not available
Quote | BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Last: | $4.43 |
---|---|
Change Percent: | 0.0% |
Open: | $4.5 |
Close: | $4.43 |
High: | $4.59 |
Low: | $4.27 |
Volume: | 4,693,079 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
News | BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
2024-04-18 16:56:16 ET Gainers: Travere Therapeutics ( TVTX ) +6% . Sabre Corporation ( SABR ) +5% . Nextracker ( NXT ) +3% . Cipher Mining ( CIFR ) +3% . BioCryst Pharmaceuticals ( BCRX ) +3% . Losers: Avidit...
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for the prophylaxis of heredita...
Message Board Posts | BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $BCRX News Article - BioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript | whytestocks | investorshangout | 05/03/2023 6:15:53 PM |
whytestocks: $BCRX News Article - BioCryst Presents New Long-term and Real-world Data Demonstrating | whytestocks | investorshangout | 02/24/2023 1:35:47 PM |
Huge buys in AH | ttubular | investorshub | 01/25/2023 11:01:34 PM |
Why is this symbol now taking a digger | VivaLasVegas | investorshub | 12/14/2022 11:39:49 PM |
whytestocks: $BCRX News Article - FDA Grants Orphan Drug Designation for BioCryst's ALK-2 Inhibitor, | whytestocks | investorshangout | 08/31/2022 2:10:56 PM |
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for the prophylaxis of heredita...
2024-03-29 02:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...